Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

2.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

3.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

4.

Real-Time and Non-invasive Monitoring of the Activation of the IRE1α-XBP1 Pathway in Individuals with Hemodynamic Impairment.

Fohlen B, Tavernier Q, Huynh TM, Caradeuc C, Le Corre D, Bertho G, Cholley B, Pallet N.

EBioMedicine. 2018 Jan;27:284-292. doi: 10.1016/j.ebiom.2017.12.023. Epub 2017 Dec 20.

5.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
6.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V.

Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1.

7.

Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium.

Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P.

BMC Cancer. 2015 Jan 31;15:26. doi: 10.1186/s12885-015-1015-5.

8.

Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.

Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V.

Clin Cancer Res. 2015 Mar 1;21(5):1087-97. doi: 10.1158/1078-0432.CCR-14-0983. Epub 2014 Sep 23.

9.

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.

Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P.

Eur J Cancer. 2014 Jul;50(10):1740-1746. doi: 10.1016/j.ejca.2014.04.007. Epub 2014 May 2.

PMID:
24797764
10.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P.

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

11.

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouché O, Landi B, Hutchison JB, Laurent-Puig P.

Clin Chem. 2013 Dec;59(12):1722-31. doi: 10.1373/clinchem.2013.206359. Epub 2013 Aug 12.

12.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group.

PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

13.

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H.

Exp Mol Pathol. 2012 Jun;92(3):275-80. doi: 10.1016/j.yexmp.2012.03.001. Epub 2012 Mar 7.

PMID:
22426079
14.

Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.

Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Salem CB, Millot F, El Harrak A, Hutchison JB, Larson JW, Link DR, Laurent-Puig P, Griffiths AD, Taly V.

Lab Chip. 2011 Jul 7;11(13):2156-66. doi: 10.1039/c1lc20128j. Epub 2011 May 19.

PMID:
21594292
15.

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism at position -765 on skin cancer after renal transplantation.

Aubin F, Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Humbert P, Saas P, Ducloux D.

J Invest Dermatol. 2010 Aug;130(8):2134-6. doi: 10.1038/jid.2010.116. Epub 2010 May 6. No abstract available.

16.

Starch nanoparticles: a review.

Le Corre D, Bras J, Dufresne A.

Biomacromolecules. 2010 May 10;11(5):1139-53. doi: 10.1021/bm901428y. Review.

PMID:
20405913
17.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P.

J Clin Oncol. 2010 May 20;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106. Epub 2010 Apr 12.

PMID:
20385995
18.

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism -765 on graft loss after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D.

Am J Transplant. 2009 Dec;9(12):2752-7. doi: 10.1111/j.1600-6143.2009.02830.x. Epub 2009 Sep 25.

19.

No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.

Pallier K, Houllier AM, Le Corre D, Cazes A, Laurent-Puig P, Blons H.

Mol Carcinog. 2009 Jul;48(7):581-5. doi: 10.1002/mc.20538.

PMID:
19353596
20.

Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma.

Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, Houdayer C, Fabre-Guillevin E, Riquet M, Dessen P, Laurent-Puig P.

BMC Med Genomics. 2008 Jun 12;1:25. doi: 10.1186/1755-8794-1-25.

21.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P.

J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.

PMID:
18202412
22.

Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma.

Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C, Laurent-Puig P; members of the ANGH group.

BMC Cancer. 2006 Nov 24;6:270.

23.

Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.

Blons H, Côté JF, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P, Danel C.

Am J Surg Pathol. 2006 Oct;30(10):1309-15.

PMID:
17001163
24.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P.

Cancer Res. 2006 Apr 15;66(8):3992-5.

25.

Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability.

Pallet N, Thervet E, Le Corre D, Knebelmann B, Nusbaum P, Tomkiewicz C, Meria P, Flinois JP, Beaune P, Legendre C, Anglicheau D.

Kidney Int. 2005 Jun;67(6):2422-33.

26.

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.

Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, Legendre C, Thervet E.

Am J Transplant. 2005 Mar;5(3):595-603.

27.

Flavor-active compounds potentially implicated in cooked cauliflower acceptance.

Engel E, Baty C, Le Corre D, Souchon I, Martin N.

J Agric Food Chem. 2002 Oct 23;50(22):6459-67.

PMID:
12381134
28.
29.

Selection of suppressor methionyl-tRNA synthetases: mapping the tRNA anticodon binding site.

Meinnel T, Mechulam Y, Le Corre D, Panvert M, Blanquet S, Fayat G.

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):291-5.

30.

Identification of an amino acid region supporting specific methionyl-tRNA synthetase: tRNA recognition.

Mellot P, Mechulam Y, Le Corre D, Blanquet S, Fayat G.

J Mol Biol. 1989 Aug 5;208(3):429-43.

PMID:
2477552
31.

Cloning of yeast lysyl- and phenylalanyl-tRNA synthetase genes.

Mirande M, Le Corre D, Riva M, Waller JP.

Biochimie. 1986 Jul-Aug;68(7-8):1001-7.

PMID:
3017455
32.

[Bone densitometry by monochromatic photon absorption. Study of a normal population and values obtained in various pathological conditions].

Renier JC, Renier G, Le Corre D, Galland F, Basle M, Delaporte D.

Rev Rhum Mal Osteoartic. 1985 Dec;52(12):675-83. French.

PMID:
4095471
34.

Association of an aminoacyl-tRNA synthetase complex and of phenylalanyl-tRNA synthetase with the cytoskeletal framework fraction from mammalian cells.

Mirande M, Le Corre D, Louvard D, Reggio H, Pailliez JP, Waller JP.

Exp Cell Res. 1985 Jan;156(1):91-102.

PMID:
3880707
36.

[Prevention of dental caries and motivation in pedodontics].

Le Corre D.

Prev Stomatol. 1979 May-Jun;5(3):31-40. Review. Italian. No abstract available.

PMID:
394146
37.

[Prevention of dental caries and motivation in pedodontics].

Le Corre D.

Inf Dent. 1978 Nov 2;60(44):23-33. French. No abstract available.

PMID:
283978

Supplemental Content

Loading ...
Support Center